Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.55 |
| ▸ | PGR | P06401 | 5/20 | 0.53 |
| ▸ | B3GNT2 | Q9NY97 | 9/20 | 0.50 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.45 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL640633 | 0.83 | B3GNT2 (0.54) | DAOPGRB3GNT2MDM2PSMB8 | |
| SCHEMBL2968866 | 0.83 | PGR (0.72) | DAOPGRB3GNT2PSMB8 | |
| SCHEMBL640117 | 0.80 | DAO (0.51) | DAOPGRB3GNT2MDM2 | |
| SCHEMBL640608 | 0.79 | MDM2 (0.65) | DAOPGRMDM2 | |
| SCHEMBL641668 | 0.76 | GABRP (0.51) | DAOPGRB3GNT2MDM2 | |
| Tert-Butyl Formate SCHEMBL27776862 | 0.76 | B3GNT2 (0.46) | DAOPGRB3GNT2MDM2 | |
| SCHEMBL640979 | 0.76 | CBX7 (0.44) | DAOPGRB3GNT2MDM2 | |
| SCHEMBL8907357 | 0.75 | CA12 (0.38) | PGRMDM2PTGDR2 | |
| SCHEMBL640092 | 0.75 | AKR1C3 (0.45) | DAOPGRB3GNT2 | |
| SCHEMBL639654 | 0.74 | CBX7 (0.55) | DAOPGRB3GNT2MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791148-B2 | Substituted benzimidazolone derivatives, medicaments comprising them and their use | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-07-29 | — | — | US | disclosed |
| CN-101528712-B | Substituted benzimidazolone derivatives, medicaments containing them and the use thereof | ABBOTT GMBH & CO KG | 2013-10-30 | — | — | CN | disclosed |
| US-20120172335-A1 | SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2012-07-05 | — | — | US | disclosed |
| US-8119676-B2 | Substituted benzimidazolone derivatives, medicaments comprising them and their use | Abbott GmbH & Co. HG (DE) | 2012-02-21 | — | — | US | disclosed |
| US-20100152168-A1 | SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE | ABBOTT GMBH & CO. KG (DE) | 2010-06-17 | — | — | US | disclosed |
| CN-101528712-A | Substituted benzimidazolone derivatives, medicaments containing them and the use thereof | ABBOTT GMBH & CO KG (DE) | 2009-09-09 | — | — | CN | disclosed |
| EP-2061769-A1 | SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE | Abbott GmbH & Co. KG (DE) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008025736-A1 | SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE | ABBOTT GMBH & CO. KG (DE) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152168-A1 | SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE | AVPR2, AVPR1B, AVPR1A | DAO 1622/4885PGR 1436/4885B3GNT2 3014/4885 |
| US-20120172335-A1 | SUBSTITUTED BENZIMIDAZOLONE DERIVATIVES, MEDICAMENTS COMPRISING THEM AND THEIR USE | AVPR2, AVPR1B, AVPR1A | DAO 1622/4885PGR 1436/4885B3GNT2 3014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.